Independence Blue Cross has begun excluding coverage for 18 months for therapies — but not cancer drugs — that have an ...

Obstructive sleep apnea (OSA) is a common sleep disorder characterized by intermittent airway blockages during sleep, leading ...

The sleep apnea diagnostic systems market is expected to grow from US$ 4.81 billion in 2023 to US$ 9.27 billion by 2033, at a ...

Tirzepatide is the active ingredient in Zepbound, the FDA approved prescription medicine for Obstructive Sleep Apnea.

For about 25 million Americans who suffer from obstructive sleep apnea, there are various effective treatments such as CPAP breathing machines, surgery, a dental mouthpiece and even an implantable pac ...

A new study found that getting eight hours of sleep a night can "significantly" improve the ability to learn a new language, ...

Inogen, Inc., a medical technology company offering innovative respiratory products for use in the homecare setting, today announced that it has received U.S. Food and Drug Administration (FDA) 510(k) ...

The FDA has approved Zepbound (tirzepatide) for the treatment of moderate to severe obstructive sleep apnea in adults with obesity.

For about 25 million Americans who suffer from obstructive sleep apnea, there are various effective treatments such as CPAP ...

Since the start of 2020, Eli Lilly’s (NYSE: LLY) stock price chart has been straight up and to the right, up 489.81% and ...

Sumitomo Pharma's Gemtesa (vibegron) has been approved by the U.S. Food and Drug Administration for men with overactive ...

Product approvals in regenerative medicine and rare diseases are among the highlights in our recap of recent FDA regulatory decisions.